COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers (LONGPDE10)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02956148
Recruitment Status : Completed
First Posted : November 6, 2016
Last Update Posted : October 10, 2019
Information provided by (Responsible Party):
CHDI Foundation, Inc.

Brief Summary:
The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand [18F]MNI-659. The study will be a follow-up, examining HDGECs from the CHDIKI1201/PET-HD-PDE10A (NCT02061722) study from 18 to 28 months after the initial PET measurement.

Condition or disease Intervention/treatment Phase
Huntington's Disease Radiation: Radioligand [18F]MNI-659 Early Phase 1

Detailed Description:
The HDGECs will perform 2 study visits: Visit 1 (screening) and Visit 2 (PET analysis utilizing the radioligand [18F]MNI-659). There will also be 2 telephone follow ups; one after Visit 1 (telephone follow-up after screening) and one after Visit 2, (telephone follow-up after PET). Study visits and telephone follow-ups will take place during a maximum of 97 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Follow-up Measurement of Brain Phosphodiesterase 10 A (PDE10A) Enzyme Levels in Huntington´s Disease Gene Expansion Carriers, 18 to 28 Months After Initial Positron Emission Tomography (PET) Measurement in CHDIKI1201/PET-HD-PDE10A (NCT02061722)
Actual Study Start Date : September 6, 2015
Actual Primary Completion Date : October 5, 2017
Actual Study Completion Date : October 5, 2017

Arm Intervention/treatment
Experimental: Radioligand [18F]MNI-659

All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.

The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.

The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%.

Radiation: Radioligand [18F]MNI-659
The effective radiation dose for the injection of [18F]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.

Primary Outcome Measures :
  1. The longitudinal changes of PDE10A enzyme availability in the caudate, putamen, and globus pallidus of Huntington's Disease Gene Expansion Carriers by comparison of the follow-up and initial PET measurements. [ Time Frame: The follow up PET measurement can be performed from 18 to 28 months after the initial PET measurement that was performed in the CHDIKI/PET-HD-PDE10A Study ]
    The HDGECs will perform 2 study visits; Visits 1 (screening) and Visit 2 (PET) and 2 telephone follow ups, one after Visit 1 (telephone follow-up after screening) and one after Visit 2, (telephone follow-up after PET) 18 to 28 months after the initial PET measurement conducted in the CHDIKI1201/PET-HD-PDE10A study. An individual subject's participation in this study will last for a maximum of 97 days

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 73 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have participated in and completed study CHDIKI1201/PET-HD-PDE10A and are capable of providing informed consent or have a legal representative authorized to give consent on their behalf.
  • Otherwise healthy according to medical history, no co-morbidity of psychotic disorders, physical examination, vital signs and laboratory assessments
  • Willing to travel to Stockholm (with a companion if requested) for PET examinations
  • Suitable physically and psychologically to travel to Stockholm and undergo PET examinations, as judged by the recruiting Investigator with attention given to symptoms of chorea and anxiety
  • Willing to comply with the use of adequate contraceptive measures

Exclusion Criteria:

  • Any disease, condition or concomitant medications that significantly compromises the function of the body systems and that, in the opinion of the Investigator might interfere with the conduct of the study or the interpretation
  • Regular use of any medication prohibited by this protocol (selective or non-selective PDE inhibitors), with the exception for erectile dysfunction medication, which may be temporarily discontinued prior to the PET measurement
  • History of anaphylactoid or anaphylactic reactions to any allergen including drugs and contrast media
  • History of other neurological condition (including brain surgery, intracranial hematoma, stroke/cerebrovascular disorders, epilepsy), co-morbidity of psychiatric disorders
  • Clinically relevant findings in hematological, biochemical testing or 12-lead ECG as determined by the evaluating physician
  • Female subjects who are breast-feeding or have a positive pregnancy test at screening or at Visit 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02956148

Layout table for location information
The Memory Clinic, Rigshopitalet
Copenhagen, Denmark
Leiden University Medical Center, Department of Neurology
Leiden, Netherlands, K5Q112
University of Oslo, Nevrologisk poliklinikk
Oslo, Norway, 0372 Oslo
Skane Universitetssjukhus Lund, Neurologiska kliniken
Lund, Sweden, SE-221 85
Karolinska Universitetssjukhus, Huddinge
Stockholm, Sweden, SE-141 86
Karolinska University Hospital
Stockholm, Sweden, SE-171 76
Uppsala University Hospital
Uppsala, Sweden
Sponsors and Collaborators
CHDI Foundation, Inc.
Layout table for investigator information
Principal Investigator: Andrea Varrone, MD, PhD Karolinska University Hospital
Study Director: Cristina Sampaio, MD, PhD CHDI Foundation, Inc.
Layout table for additonal information
Responsible Party: CHDI Foundation, Inc. Identifier: NCT02956148    
Other Study ID Numbers: CHDIKI1401
First Posted: November 6, 2016    Key Record Dates
Last Update Posted: October 10, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders